Increasing Prevalence Of Age-related Macular Degeneration Driving Market Growth: An Emerging Driver Transforming The Choroidal Neovascularization Market Landscape

We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Projected Growth of the Choroidal Neovascularization Market?
The market for choroidal neovascularization has seen robust growth in recent times. It is projected to increase from $3.37 billion in 2024 to $3.61 billion in 2025, experiencing a compound annual growth rate (CAGR) of 8.1%. The expansion in the historic period has links to the growing number of sedentary lifestyle-related diseases, an increasing number of cases for age-related macular degeneration, a surge in retinal illnesses, an aging population, escalated costs for eye care, and broadening education and screening programs.

Forecasted to witness robust growth in the coming years, the choroidal neovascularization market is set to scale up to $5.64 billion in 2029, registering a compound annual growth rate (CAGR) of 7.7%. This surge in the prediction period is a result of rising patient consciousness, widened use of optical coherence tomography angiography, escalating demand for minimally invasive procedures, supportive reimbursement schemes, and an expanding elderly population. The introduction of intravitreal anti-vascular endothelial (VEGF) therapies, novel gene remedies, gene therapy strategies, telemedicine utilisation, development of combined therapies, and personalized treatment plans are the main trend-setters in the forecasted period.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21142

What Are the Different Choroidal Neovascularization Market Segments?
The choroidal neovascularization market covered in this report is segmented -

1) By Treatment Type: Anti-Angiogenic Therapy, Laser Photocoagulation, Photodynamic Therapy, Verteporfin Sodium, Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium
2) By Indication: Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), Central Serous Chorioretinopathy (CSC), Polypoidal Choroidal Vasculopathy (PCV), Myopic Macular Degeneration (MMD), Other Indications
3) By Route Of Administration: Intravitreal, Subconjunctival, Periocular, Oral
4) By End User: Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers, Research Centers

Subsegments:
1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium
2) By Laser Photocoagulation: Thermal Laser Photocoagulation, MicroPulse Laser Therapy
3) By Photodynamic Therapy (PDT): Standard PDT, Low-Fluence PDT, Half-Dose PDT
4) By Verteporfin Sodium: Intravenous Administration, Combination Therapy With Anti-VEGF
5) By Ranibizumab: Monthly Dosing, As-Needed Dosing, Treat-and-Extend Regimen
6) By Bevacizumab: Off-Label Use, Compounded Intravitreal Injections
7) By Aflibercept: Fixed-Dosing Regimen, Treat-and-Extend Regimen
8) By Pegaptanib Sodium: Monotherapy, Combination Therapy

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp

What Are the Primary Drivers Shaping the Choroidal Neovascularization Market?
The growth of the choroidal neovascularization (CNV) market is anticipated to be stimulated by the escalating incidences of age-related macular degeneration (AMD). AMD is an eye condition that gradually impairs the macula, leading to a loss of central vision, particularly in the elderly. The escalating incidences of AMD are attributed to an aging population, heightened life expectancy, changes in lifestyle, genetic predisposition, and increased exposure to environmental hazards. Choroidal neovascularization (CNV) aids patients with AMD by facilitating the development of wet AMD, a condition where abnormal blood vessel growth under the retina causes vision impairment. This necessitates advanced treatments like anti-VEGF therapy to regulate CNV and retard the progress of AMD, thereby conserving central vision in impacted individuals. For example, as reported by the National Institutes of Health, a US government agency, in September 2022, it is projected that by 2040, AMD incidences might touch 300 million, and by 2050, around 5.4 million Americans could be affected. Consequently, the rising incidences of AMD are propelling the growth of the CNV market.

Which Companies Are Leading in the Choroidal Neovascularization Market?
Major companies operating in the choroidal neovascularization market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer Aktiengesellschaft, Novartis AG, Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Chugai Pharmaceutical Co. Ltd., Alcon Inc., Genentech Inc., Bausch + Lomb Incorporated, Samsung Bioepis Co. Ltd., Santen Pharmaceutical Co. Ltd., Apellis Pharmaceuticals Inc., Kodiak Sciences Inc., Xbrane Biopharma AB, Allergan Inc., Adverum Biotechnologies Inc., Clearside Biomedical Inc., Sylentis S.A.

What Trends Are Expected to Dominate the Choroidal Neovascularization Market in the Next 5 Years?
Leading firms in the choroidal neovascularization market are concentrating their efforts on creating advanced therapies like photodynamic therapy. Their goal is to provide ophthalmologists with precise and effective treatment tools that enhance patient results and treatment delivery. Photodynamic therapy (PDT), a medical procedure, utilizes a photosensitizing compound and light to destroy abnormal or cancerous cells. For instance, in February 2023, Bausch & Lomb, a TH*Care organization from Canada, along with Modulight, a biomedical firm from Finland, disclosed that the ML6710i photodynamic laser received approval from the U.S. Food and Drug Administration. This treatment has been authorized for use with Bausch + Lomb's VISUDYNE therapy, specifically developed for dealing with age-related macular degeneration-induced choroidal neovascularization. This contemporary, portable ophthalmic laser adopts a targeted method to treat abnormal ocular blood vessels, which aids in averting further advancement of the disease and in preserving vision.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report

What Are the Top Revenue-Generating Geographies in the Choroidal Neovascularization Market?
North America was the largest region in the choroidal neovascularization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Choroidal Neovascularization Market?
2. What is the CAGR expected in the Choroidal Neovascularization Market?
3. What Are the Key Innovations Transforming the Choroidal Neovascularization Industry?
4. Which Region Is Leading the Choroidal Neovascularization Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.